Iovance falls after Q2 revenue miss, wider loss

Shares of drugmaker Iovance Biotherapeutics IOVA.O fall 30.7% to $1.83 in extended trading

Co reports Q2 revenue of $60 million, falling short of analysts' average estimate of $69.79 million, according to data compiled by LSEG

Posts Q2 loss of 33 cents, analysts expected a loss of 28 cents

Co says it is reducing its workforce by 19% by the third quarter of this year

IOVA reiterates total product revenue guidance within the range of $250 million to $300 million vs est of $300.18 million

Stock down 64.3% YTD